Intensive CTD immunotherapy was the only factor that remained significant after multivariate logistic regression, and thus was confirmed to be independently associated with a lower risk NT-proBNP trajectory (p = 0.048, odds ratio (OR) = 0.027, 95% confidence interval (CI): 0.001–0.963) (Table 2), which indicated a positive response of CTD-PAH patients to intensive CTD immunotherapy partly shown by an earlier NT-proBNP remission. This evidence concerns the gene NPPB and pulmonary arterial hypertension.